tetano
Editor, Senior Moderator
Drugs Ther Perspect
. 2020 Sep 14;1-5.
doi: 10.1007/s40267-020-00777-z. Online ahead of print.
Severe prolonged neutropenia following administration of tocilizumab in a patient affected by COVID-19: a case report and brief review of the literature
Luca Bernardo[SUP] 1 [/SUP], Stefania Del Sesto[SUP] 2 3 [/SUP], Laura Giordano[SUP] 1 [/SUP], Anna Rita Benincaso[SUP] 1 [/SUP], Piero Biondi[SUP] 1 [/SUP], Vinicio Goj[SUP] 1 [/SUP], Francesca Ferrara[SUP] 1 [/SUP], Antonella Talenti[SUP] 1 [/SUP], Antonella Grisolia[SUP] 4 [/SUP], Paolo Antonio Ascierto[SUP] 5 [/SUP]
Affiliations
Abstract
Tocilizumab is one of the newest therapeutic options for the acute respiratory distress syndrome (ARDS) caused by the recently discovered severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) β-coronavirus. Several trials are currently ongoing to assess the efficacy and safety profile of tocilizumab in treating ARDS. In this article, we present the case of a Black patient with acute pneumonia who benefited greatly from tocilizumab, but developed severe prolonged neutropenia. Considering the increasing use of tocilizumab among patients with coronavirus disease 2019 (COVID-19), this case warrants further research regarding the possible adverse hematological effects that need to be monitored in order to prevent secondary infections.
. 2020 Sep 14;1-5.
doi: 10.1007/s40267-020-00777-z. Online ahead of print.
Severe prolonged neutropenia following administration of tocilizumab in a patient affected by COVID-19: a case report and brief review of the literature
Luca Bernardo[SUP] 1 [/SUP], Stefania Del Sesto[SUP] 2 3 [/SUP], Laura Giordano[SUP] 1 [/SUP], Anna Rita Benincaso[SUP] 1 [/SUP], Piero Biondi[SUP] 1 [/SUP], Vinicio Goj[SUP] 1 [/SUP], Francesca Ferrara[SUP] 1 [/SUP], Antonella Talenti[SUP] 1 [/SUP], Antonella Grisolia[SUP] 4 [/SUP], Paolo Antonio Ascierto[SUP] 5 [/SUP]
Affiliations
- PMID: 32952393
- PMCID: PMC7487439
- DOI: 10.1007/s40267-020-00777-z
Abstract
Tocilizumab is one of the newest therapeutic options for the acute respiratory distress syndrome (ARDS) caused by the recently discovered severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) β-coronavirus. Several trials are currently ongoing to assess the efficacy and safety profile of tocilizumab in treating ARDS. In this article, we present the case of a Black patient with acute pneumonia who benefited greatly from tocilizumab, but developed severe prolonged neutropenia. Considering the increasing use of tocilizumab among patients with coronavirus disease 2019 (COVID-19), this case warrants further research regarding the possible adverse hematological effects that need to be monitored in order to prevent secondary infections.